Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Roumier

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Oncotarget|October 22, 2015
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Delphine Lebon, Christophe Roumier, et al.
Hemasphere|December 26, 2022
Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated IntensivelyReinaldo Dal Bello, Kim Pacchiardi, Clémentine Chauvel, et al.
Journal for Immunotherapy of Cancer|July 8, 2022
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemiaRim Trad, Walid Warda, Vincent Alcazer, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Blood Advances|March 9, 2021
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesisFlorian Renosi, Anne Roggy, Ambre Giguelay, et al.
Blood|October 24, 2002
M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)Christophe Roumier, Virginie Eclache, Michelle Imbert, et al.
Haematologica|February 16, 2015
CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorderGuillaume Lefèvre, Marie-Christine Copin, Christophe Roumier, et al.
Leukemia|March 1, 2020
CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasmElodie Bôle-Richard, Maxime Fredon, Sabeha Biichlé, et al.
Blood|April 10, 2016
Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasmsAnouk Emadali, Neda Hoghoughi, Samuel Duley, et al.
Haematologica|October 15, 2020
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscapeLoria Zalmaï, Pierre-Julien Viailly, Sabeha Biichle, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Oncotarget|October 22, 2015
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French AssociationHouria Debarri, Delphine Lebon, Christophe Roumier, et al.
Hemasphere|December 26, 2022
Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated IntensivelyReinaldo Dal Bello, Kim Pacchiardi, Clémentine Chauvel, et al.
Journal for Immunotherapy of Cancer|July 8, 2022
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemiaRim Trad, Walid Warda, Vincent Alcazer, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Blood Advances|March 9, 2021
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesisFlorian Renosi, Anne Roggy, Ambre Giguelay, et al.
Blood|October 24, 2002
M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)Christophe Roumier, Virginie Eclache, Michelle Imbert, et al.
Haematologica|February 16, 2015
CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorderGuillaume Lefèvre, Marie-Christine Copin, Christophe Roumier, et al.
Leukemia|March 1, 2020
CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasmElodie Bôle-Richard, Maxime Fredon, Sabeha Biichlé, et al.
Blood|April 10, 2016
Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasmsAnouk Emadali, Neda Hoghoughi, Samuel Duley, et al.
Haematologica|October 15, 2020
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscapeLoria Zalmaï, Pierre-Julien Viailly, Sabeha Biichle, et al.
Pageof 6